The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach

Gordon, Kenneth B.; Ruderman, Eric

doi:10.1016/j.jaad.2005.10.052

Cited by 35 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Expression of proinflammatory cytokine mRNA, including TNF-α, was higher in the synovial tissue of patients with psoriatic arthritis than in normal synovium (79). Findings from clinical trials targeting the TNF-α-TNF-αR (66,67) point to a central role for TNF-α in the pathogenesis of psoriatic arthritis. The relationship between local and systemic markers of inflammation, the levels of cytokines and matrix metalloproteinases (MMPs) in synovial fluid, were examined in psoriatic arthritis.…”

Section: Cytokines and Chemokines In Psoriasis And Psoriatic Arthritismentioning

confidence: 98%

“…2). The central role of TNF-α is confirmed by the therapeutic efficacy of TNF-α-targeting agents (etanercept, infliximab, and adalimumab) (66)(67)(68). This cytokine is produced by macrophages, monocytes, mature DC (including Langerhans cells), polymorphonuclear cells, mast cells, NK cells, activated T-cells, keratinocytes, and endothelial cells (44,(69)(70)(71)(72)(73).…”

Section: Cytokines and Chemokines In Psoriasis And Psoriatic Arthritismentioning

confidence: 99%

See 1 more Smart Citation

Immunopathogenesis of Psoriasis and Psoriatic Arthritis and Pharmacological Perspectives

Loffredo

Ayala²,

Genovese³

et al. 2011

Reumatismo

View full text Add to dashboard Cite

Section: Cytokines and Chemokines In Psoriasis And Psoriatic Arthritismentioning

confidence: 98%

Section: Cytokines and Chemokines In Psoriasis And Psoriatic Arthritismentioning

confidence: 99%

Immunopathogenesis of Psoriasis and Psoriatic Arthritis and Pharmacological Perspectives

Loffredo

Ayala²,

Genovese³

et al. 2011

Reumatismo

View full text Add to dashboard Cite

“…In addition, it is used to prevent rejection following bone marrow transplantation and in the prophylaxis of host-versus-graft disease. It is also used in the treatment of psoriasis, atopic dermatitis, encephalomyelitis, rheumatoid arthritis, nephrotic syndrome, and uveoretinitis (Cather et al, 2001;Gordon and Ruderman, 2006). CsA is a potent inhibitor of cell-mediated immunity, and a less potent inhibitor of humoral immunity.…”

Section: Clinical Use and Mechanism Of Actionmentioning

confidence: 99%

Mechanisms of Calcineurin Inhibitor Nephrotoxicity in Chronic Allograft Injury

Slattery¹,

Cassidy²,

Johnston³

et al. 2012

Chronic Kidney Disease and Renal Transplantation

View full text Add to dashboard Cite

“…The PASI is currently regarded as one of the most reliable and consistent outcome measures, thus is commonly used in clinical studies. 29 It is a composite index, ranging from 0 to 72, that assigns a score to the three main characteristics of a psoriatic plaque (erythema, thickness and scaling, scored from 0 to 4), weighted by its extension on the four main body areas (head, trunk, upper extremities, and lower extremities). Higher PASI scores are associated with more severe disease.…”

Section: Dovepressmentioning

confidence: 99%

“…It can go from 0 to 30, with higher scores indicative of poor quality of life. 29 An integral assessment is necessary to label with accuracy the severity of the psoriasis in each individual, and therefore select the appropriate treatment modality based on this result.…”

Section: Dovepressmentioning

confidence: 99%

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis

Krulig

Gordon

2010

View full text Add to dashboard Cite

Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated the essential role of specific cytokines in the development of this complex disease, including TNF-α, interleukin-23 (IL-23), and potentially, IL-22. These are all part of a newly defined autoimmune pathway directed by specialized T cells called Th17 helper T cells. Ustekinumab is a fully human monoclonal antibody that targets IL-12 and IL-23, thus targeting both Th1 and Th17 arms of immunity. It has a promising efficacy and safety profile that not only represents a valuable treatment alternative, but also a continuation in our constantly evolving understanding of this disorder. Aims: To review the emerging evidence supporting the use of ustekinumab in the management of moderate to severe plaque psoriasis. Evidence review: There is clear evidence that ustekinumab is effective in the treatment of moderate to severe psoriasis. Phase III trials (PHOENIX 1 and 2) demonstrated a statistically significant difference between Psoriasis Area and Severity Index (PASI) 75 responses achieved by patients receiving ustekinumab, given as a 45 mg or 90 mg subcutaneous injection every 12 weeks, than their placebo counterparts. Treatment with this novel agent resulted in a rapid onset of action, with over 60% of treated patients attaining Physician's Global Assessment (PGA) scores of "cleared" or "minimal" by week 12. Quality of life assessments paralleled clinical improvements. Clinical potential: Ustekinumab is an effective and efficient therapeutic option for patients with moderate to severe psoriasis. Although further studies are required to establish ustekinumab's place in the therapy of psoriasis, with its convenient dosing schedule and rapid onset of action, this drug could provide a great addition to the current therapeutic armamentarium available for psoriatic patients.

show abstract

The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach

Cited by 35 publications

References 22 publications

Immunopathogenesis of Psoriasis and Psoriatic Arthritis and Pharmacological Perspectives

Immunopathogenesis of Psoriasis and Psoriatic Arthritis and Pharmacological Perspectives

Mechanisms of Calcineurin Inhibitor Nephrotoxicity in Chronic Allograft Injury

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis

Contact Info

Product

Resources

About